Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOPTRAFFIC-1: SX-682 and Nivolumab in mCRC
NCT04599140Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2020
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SX-682 in colorectal cancer (CRC), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2020; status: active, not recruiting.
02
Drugs
SX-682
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04599140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04599140.